Phenobarbital: Nursing Drug Guide, Respiratory Depression & NCLEX Review

Phenobarbital is the generic name in most orders.

Common brands: Luminal (oral/tablet traditions), phenobarbital sodium injection (65 mg/mL and 130 mg/mL vials). Verify whether the order is oral maintenance versus parenteral loading for status—the administration rules differ sharply.

Phenobarbital is a long-acting barbiturate used as sedative, hypnotic, preanesthetic agent, and anticonvulsant. Parenteral routes are for situations where oral therapy is impossible or when prompt anticonvulsant effect is needed.

↔On a small screen, swipe or scroll sideways to see the full table.

Barbiturates are nonselective CNS depressants. Phenobarbital depresses the sensory cortex, decreases motor activity, and at subhypnotic doses exhibits selective anticonvulsant activity—increasing seizure threshold and limiting spread of seizures in generalized tonic-clonic epilepsy. Barbiturates are direct respiratory depressants on the medullary respiratory center; high doses may abolish response to carbon dioxide. Phenobarbital induces hepatic microsomal enzymes, increasing metabolism of itself and many co-medications (including oral anticoagulants and other antiepileptic drugs).

Doses must be individualized by age, weight, and condition. Parenteral routes are used only when oral administration is impossible or impractical. Institutional protocols and product formulations may vary.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Confirm indication (maintenance anticonvulsant vs acute loading vs sedation) and route (oral vs IM vs IV)
• Review respiratory status, baseline sedation score, and airway patency; ensure resuscitation equipment available for IV doses
• Baseline liver function tests when hepatic impairment suspected; reduce dose in hepatic or severe renal disease per labeling
• Check phenobarbital level when ordered; target anticonvulsant range 10–25 µg/mL
• Perform medication reconciliation for CNS depressants, MAO inhibitors, oral anticoagulants, and interacting AEDs
• Verify neonates will not receive benzyl alcohol–containing injection unless prescriber documents risk–benefit and alternative unavailable

Contraindications (DailyMed)

• Known barbiturate sensitivity
• Manifest or latent porphyria
• Marked hepatic impairment or severe respiratory distress with dyspnea or obstruction
• Large doses in nephritic subjects
• Intra-arterial administration (gangrene risk); subcutaneous administration not recommended
• Known previous addiction to sedative-hypnotics (ordinary doses may be ineffectual)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Routes: Oral (tablets/elixir where available), intramuscular, or slow intravenous per product. Parenteral solutions are highly alkaline—avoid extravasation and never administer intra-arterially.

• IV: Rate not to exceed 60 mg/min in adults; use large vein; aspirate to avoid intra-arterial injection; stop if limb pain or white/cyanotic hand occurs
• Status epilepticus: Give loading dose over 10–15 minutes per prescriber; do not continue bolusing until seizures stop—wait for anticonvulsant effect before second dose
• IM: Deep injection into large muscle; do not exceed 5 mL at one site
• Inspect vial for particulate matter and discoloration before use
• Follow controlled-substance (Schedule IV) counting and high-alert medication administration protocols per facility

• Seizure cessation or reduced seizure frequency without excessive sedation
• Phenobarbital level within prescriber target (often 10–25 µg/mL for anticonvulsant use)
• Stable respirations, oxygen saturation, and blood pressure during and after IV administration
• Controlled sedation for indicated preoperative or short-term hypnotic use
• No progressive altered mental status, hypotension, or apnea

Hold phenobarbital and obtain urgent prescriber/pharmacist direction when any of the following appear:

• Respiratory rate fall, shallow breathing, apnea, or oxygen desaturation after dose
• Marked sedation, inability to arouse, or new severe confusion disproportionate to clinical context
• Hypotension, bradycardia, or shock syndrome after IV bolus or rapid infusion
• Extravasation, limb pain, white hand, or suspected intra-arterial injection
• Level above therapeutic range with toxicity signs (nystagmus, ataxia, coma)
• Exfoliative dermatitis or Stevens-Johnson syndrome signs—discontinue per labeling

↔On a small screen, swipe or scroll sideways to see the full table.

Acute overdosage manifests as CNS and respiratory depression progressing to Cheyne-Stokes respiration, areflexia, miosis (though paralytic dilation in severe poisoning), oliguria, tachycardia, hypotension, hypothermia, and coma. Lethal blood levels are generally greater than 80 µg/mL and usually 100–200 µg/mL.

Labeling guidance

• No specific antidote—management is supportive
• Maintain airway with assisted respiration and oxygen; monitor vitals and fluid balance
• Forced diuresis and urine alkalinization may aid elimination when renal function is normal
• Hemodialysis may be used in severe intoxication; analeptic agents are not recommended
• Contact local poison control / medical toxicology services per facility protocol

• Phenobarbital vs phenytoin vs pentobarbital — independent double-check on all AED and barbiturate orders
• mg vs mL — injection concentrations 65 mg/mL and 130 mg/mL; verify pump rate in mg/min not mL/min for IV limits
• Loading dose vs maintenance dose — status orders may be mg/kg over minutes; chronic orders are mg/day PO
• Continuous bolus until seizure stops — common workflow error; label and pump programming must reflect slow controlled infusion

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous or frequent respiratory rate, SpO₂, and sedation level during IV therapy
• Blood pressure and heart rate during slow IV administration
• Phenobarbital serum levels when anticonvulsant control changes or toxicity suspected (target often 10–25 µg/mL)
• Complete neurological assessment including gait, nystagmus, and mental status
• Signs of withdrawal when tapering long-term therapy
• Hematologic and hepatic labs with prolonged therapy per prescriber

Document

• Exact dose, route, infusion rate (mg/min), vein site, and patient response
• Seizure activity before and after dose with time stamps
• Level results and concurrent CNS depressants
• Controlled-substance count and waste

• Do not drive or operate machinery until response to medication is known
• Do not drink alcohol or take other sedatives without prescriber approval
• Do not stop suddenly—withdraw gradually to prevent seizures and withdrawal
• Report excessive drowsiness, slurred speech, unsteadiness, or breathing difficulty immediately
• Oral contraceptives may be less effective—discuss backup methods
• Keep medication secure; phenobarbital is a controlled substance with dependence potential
• Breastfeeding parents: watch the infant for excessive sleepiness, poor feeding, or slow weight gain; report concerns promptly

Do not give and contact the prescriber/pharmacist when:

Hold parameters can vary by institution. Follow prescriber orders, pharmacy guidance, and local policy.

Practice NCLEX-style clinical judgment practice for phenobarbital using a tabbed case panel (MAR, labs, history, nursing notes), then priority action, SATA cue recognition, respiratory trend interpretation, matrix urgency judgment, IV rate documentation, and seizure-loading cloze—focused on respiratory depression and the IV bolus-until-seizures-stop trap.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.